Abstract
Effective, pharmacologic approaches to the treatment of cerebellar ataxia are lacking or inadequate. We recently reported preliminary evidence that tandospirone citrate (tandospirone), a 5-HT1A agonist, improved cerebellar ataxia in patients with Machado-Joseph disease (MJD). In the course of that study, we found that such treatment also alleviated the pain associated with cold sensations in the legs, insomnia, anorexia, and depression, all of which are thought to be mediated through activation of the 5-HT1A receptor. In this paper, we reviewed the few published clinical trials that involved the use of 5-HT 1A receptor agonists for the treatment of cerebellar ataxia, and discussed the current theories regarding their mechanism of action. Cortical cerebellar atrophy (CCA) was reported, in a double-blind study, to be amenable to treatment with tandospirone. Other types of spinocerebellar degeneration (SCD) i.e., olivopontocerebellar atrophy (OPCA) and Machado-Joseph disease (MJD) have also been reported to respond to the drug, but these have been small studies. Responsive patients exhibited only mild ataxia. The doses of 5-HT1A agonists that have been used successfully ranged from 12.5 mg/day to 60 mg/day (or 1mg/kg), and were well tolerated by most patients.
Similar content being viewed by others
References
Waragai M, Ogawara K, Takaya Y, Hayashi M. Efficacy of TRH-T for spinocerebellar degeneration —the relation between clinical features and effect of TRH therapy. Rinsho Shinkeigaku. 1997;37:587–94. [In Japanese]
Kanazawa I, Satoyoshi E, Hirayama K, et al. Clinical evaluation of taltirelin hydrate (TA-0910) in patients with spinocerebellar degeneration —A multi-center double-blind comparative study with placebo. Rinsyo Iyaku. 1997; 13:4169–24. [In Japanese]
Fukuchi I, Asahi T, Kawashima K, Kawashima Y, Yamamura M, Matsuoka Y, Kinoshita K. Effects of Taltirelin hydrate (TA-0910), a novel thyrotropin-releasing hormone analog, onin vivo dopamine release and turnover in rat brain. Arzneimittelforschung. 1998;48:353–9.
Trouillas P. L-5-Hydroxytryptophan treatment in cerebellar ataxia: Clinical and etiological correlations. Mov Disord. 1990;5(Suppl. 1):6.
Trouillas P, Brudon F, Adeleine P. Improvement of cerebellar ataxia with levorotatory form of 5-hydroxytryptophan. A double-blind study with quantified data processing. Arch Neurol. 1988;45:1217–22.
Lou JS, Goldfarb L, McShane L, Gatev P, Hallett M. Use of buspirone for treatment of cerebellar ataxia. An open-label study. Arch Neurol. 1995;52:982–8.
Trouillas P, Xie J, Adeleine P, et al. Buspirone, a 5-hydroxytryptamine1A agonist, is active in cerebellar ataxia. Results of a double-blind drug placebo study in patients with cerebellar cortical atrophy. Arch Neurol. 1997; 54:749–52.
Trouillas P, Xie J, Adeleine P. Buspirone, a serotonergic 5-HT1A agonist, is active in cerebellar ataxia. A new fact in favor of the serotonergic theory of ataxia. Prog Brain Res. 1997;114:589–99.
Friedman JH. Machado-Joseph disease/spinocerebellar ataxia 3 responsive to buspirone. Mov Disord. 1997;12:613–14.
Saito Y, Miwa S, Yamana T, Hasegawa Y, Takagi S. Clinical therapeutical trial of oral tandospirone for cerebellar ataxia. Nagoya Shiritu Byouin Kiyou. 1998;21:5–8. [In Japanese]
Takei A, Honma S, Kawashima A, et al. Beneficial effects of tandospirone on ataxia of a patient with Machado-Joseph disease. Psychiatry Clin Neurosci. 2002;56:181–5.
Takei A, Fukazawa T, Hamada T, Yabe I, Tashiro K. ‘Drug holiday’ effects of tandospirone in a patient with Machado-Joseph disease. Psychiatry Clin Neurosci. 2003;57:607–8.
Takei A, Fukazawa T, Hamada T, Sohma H, Yabe I, Sasaki H, Tashiro K. Effects of tandospirone on ‘5-HT1A receptor-associated symptoms’ in patients with Machado-Joseph disease. An open-label study. Clin Neuropharmacol. 2004;27:9–13.
Traber J, Glaser T. 5-HT1A-related anxiolytics. Trends Pharmacol Sci. 1987;8:432–7.
Parks CL, Robinson PS, Sibille E, Shenk T, Toth M. Increased anxiety of mice lacking the serotonin1A receptor. Proc Natl Acad Sci USA. 1998;95:10734–9.
Bjorvatn B, Fagerland S, Eid T, Ursin R. Sleep/waking effects of a selective 5-HT1A receptor agonist given systemically as well as perfused in the dorsal raphe nucleus in rats. Brain Res. 1997;770:81–8.
Sørensen E, Grønli J, Bjorvatn B, Bjørkum A, Ursin R. Sleep and waking following microdialysis perfusion of the selective 5-HT1A receptor antagonist p-MPPI into the dorsal raphe nucleus in the freely moving rat. Brain Res. 2001; 897:122–30.
Vickers SP, Clifton PG, Dourish CT. Behavioural evidence that d-fenfluramine-induced anorexia in the rat is not mediated by the 5-HT1A receptor subtype. Psychopharmacology. 1996;125:168–75.
Glennon RA, Lucki I. Behavioural models of serotonin receptor activation. In: Sanders-Bush E, editor. The serotonin receptors. Clifton, NJ: Humana Press; 1988. pp 253–93.
Lucki I. 5-HT1 receptors and behaviour. Neurosci Biobehav Rev. 1992;16:83–93.
Giordano J, Rogers L. Putative mechanisms of buspironeinduced antinociception in the rat. Pain. 1992;50:365–72.
Trouillas P, Takayanagi T, Hallett M, et al. International cooperative ataxia rating scale for pharmacological assessment of the cerebellar syndrome. The ataxia neuropharmacology committee of the world federation of neurology. J Neurol Sci. 1997;145:205–11.
Zung WWK. A self-rating depression scale. Arch Gen Psychiat. 1963;12:63–70.
Wieland S, Fischette CT, Lucki I. Effect of chronic treatments with tandospirone and imipramine on serotoninmediated behavioral responses and monoamine receptors. Neuropharmacology. 1993;32:561–573.
Pike VW, MaCarron JA, Lammerstma AA, et al. First delineation of 5-HT1A receptors in human brain with PET and [11C]WAY 100635. Eur J Pharmacol. 1995;283:R1–3.
Burnet PW, Eastwood SL, Lacey K, Harrison PJ. The distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain. Brain Res. 1995;676:157–68.
Miquel MC, Doucet E, Riad M, Adrien J, Verge D, Hamon M. Effect of the selective lesion of serotoninergic neurons on the regional distribution of 5-HT1A receptor mRNA in the rat brain. Brain Res Mol Brain Res. 1992; 14:357–62.
Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999;38:1083–152.
Maura G, Raiteri M. Serotonin 5-HT1D and 5-HT1A receptors respectively mediate inhibition of glutamate release and inhibition of cyclic GMP production in rat cerebellum in vitro. J Neurochem. 1996;66:203–09.
Maura G, Roccatagliata E, Ulivi M, Raiteri M. Serotoninglutamate interaction in rat cerebellun: Involvement of 5-HT1 and 5-HT2 receptors. Eur J Pharmacol. 1988:31–8.
Raiteri M, Maura G, Barzizza A. Activation of presynaptic 5-hydroxytryptamine1-like receptors on glutamatergic terminals inhibits N-methyl-D Aspartate-induced cyclic GMP production in rat cerebellar slices. J Pharmacol Exp Ther. 1991; 257:1184–8.
Darrow EJ, Strahlendorf HK, Strahlendorf JC. Response of cerebellar Purkinje cells to serotonin and the 5-HT1A agonists 8-OH-DPAT and ipsapironein vitro. Eur J Pharmacol. 1990;175:145–53.
Monte TL, Rieder CR, Tort AB, et al. Use of fluoxetine for treatment of Machado-Joseph disease: an open-label study. Acta Neurol Scand. 2003;107:207–10.
Bier JC, Dethy S, Hildebrand J, Jacquy J, Manto M, Martin JJ, Seeldrayers P. Effects of the oral form of ondansetron on cerebellar dysfunction. A multi-center double-blind study. J Neurol. 2003;250:693–7.
Drevets WC, Frank E, Price JC, et al. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry. 1999;46:1375–87.
Sargent PA, Kjaer KH, Bench CJ, et al. Brain serotonin 1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry. 2000;57:174–80.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Takei, A., Hamada, T., Yabe, I. et al. Treatment of cerebellar ataxia with 5-HT1A agonist. Cerebellum 4, 211–215 (2005). https://doi.org/10.1080/14734220500222318
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1080/14734220500222318